

Carmel sells and manufactures the drug handling system PhaSeal® to the health care sector. The system is a closed system for the safe handling of hazardous drugs, minimizing the leakage and spread of aerosols into the working environment and allowing a more efficient handling near the patient. Carmel Pharma was founded in 1994 and its major owners are Investor Growth Capital (the venture capital arm of Investor AB) and 3i Group plc. For more information on PhaSeal and Carmel Pharma please visit: www.carmelpharma.com

Göteborg, September 14, 2006

Carmel Pharma signs breakthrough cooperation agreement with German pharmacies

VZA, a German association of leading retail pharmacies specialised in the preparation of cytotoxic pharmaceuticals, has signed a cooperation agreement with Carmel Pharma to support the implementation of Carmel Pharma's PhaSeal system with its 250 members throughout Germany.

VZA is in the forefront of technology and safety and has decided to add PhaSeal to its already advanced set-ups. German safety regulations and guidelines for hazardous drugs are among the strictest and most detailed in the world today, but with new scientific data available and new European legislation on its way, VZA intends to keep its leading position through its continuous work on safety and quality issues.

"It was natural to choose PhaSeal, the only documented closed system for handling hazardous drugs, as our partner as we look to further enhance safety measures with our members," says Mr. Peter Eberwein, Chairman of VZA. The association's 250 members reportedly account for more than 60 % of the cytotoxic preparations in Germany for both smaller and very large facilities. The common denominator is their quest for continuous improvement in safety for patients and health care workers.

PhaSeal, developed by Carmel Pharma, is a closed system for the safe handling of hazardous drugs. PhaSeal is marketed and sold in more than 30 countries worldwide, with a major presence in the United States for several years.

"We are very pleased to team up with the highly professional and conscientious VZA membership in Germany as their view of safety, and commitment to it, is second to none," says Dan Pitulia, CEO of Carmel Pharma.

For further information:

Dan Pitulia, CEO
Carmel Pharma AB
+46-31 703 04 00 (office)
+46-709 720 838 (mobile)

Ulf Järnberg, President
Carmel Pharma GmbH
+49-69 58 700 750 (office)
+49-160 9631 0544 (mobile)

Peter Eberwein, Chairman
VZA
www.vza-info.de